- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04228523
Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients? (ETPARK-REMED) (ETPARK-REMED)
Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients?
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management.
The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug.
This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Occitanie
-
Toulouse, Occitanie, France, 31059
- Toulouse University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
- Patients who are already in therapeutic education program ETPARK,
- Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
- Patients with health insurance,
- Patients who have signed a written informed consent form.
Exclusion Criteria:
- Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
- Patients who has already done workshop on Parkinson disease drug (program ETPARK)
- Patients already included in clinical trial during the study,
- Patients who have severe psychiatric disorders or dopaminergic psychosis,
- Patients with cognitive impairment,
- Patients unable to complete the various scales used in the study,
- Patients under juridical protection,
- Women pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Therapeutic education workshop
Two group receive therapeutic education workshop already existing in Toulouse University Hospital
|
Workshop on Parkinson disease drug has several educative sequences (lasting 4hours).
At the end, one patient explains its tips and tricks about its drug management |
Other: Speaking Therapy
One group receive speaking therapy already existing in Toulouse University Hospital
|
Speaking group is leaded by a psychologist from Centre Expert Parkinson (lasting 2 hours).
This specific time is an exchange between patients with Parkinson disease who feel free to come.
It is about sharing its own experience.
It is a very special moment, confidential and kindly where patients don't judge themselves and speak only if they want to.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of Drug representation in Patients : BMQ
Time Frame: Three months
|
Evolution of Drug representation through the Believe about Medicines Questionnaire (BMQ) compared to the control group. Evolution will be compared between the Baseline and the end of the study BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree". |
Three months
|
Evolution of Drug representation in Patients : Verbal association
Time Frame: Three months
|
Evolution of Drug representation through verbal association tasks compared to the control group.
Evolution will be compared between the Baseline and the end of the study
|
Three months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug representation in caregivers : Verbal association
Time Frame: Day 1
|
Drug representation through verbal association tasks.
|
Day 1
|
Drug representation in caregivers : BMQ
Time Frame: Day 1
|
Drug representation through the Believe about Medicines Questionnaire (BMQ).
BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree".
|
Day 1
|
Knowledge about the disease
Time Frame: three months
|
Evolution between Baseline and three months with a test created for the study.
The test have 8 questions with two answers possible : True or False
|
three months
|
Evolution in life quality : VAS
Time Frame: three months
|
Evolution in life quality evaluate with Visual Analog Scale (VAS), 0 being the worst quality of life and 10 the best quality of life he can have. Evolution between Baseline and three months |
three months
|
Evolution in life quality : PDQ-(39)
Time Frame: three months
|
Evolution in life quality evaluate with Parkinson Disease Quotation (PDQ)-39 with thirty-nine items coded from 1 " "always" to 5 "never". The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication. Evolution between Baseline and three months |
three months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Christine Brefel-Courbon, MD, Univeristy Hospital Toulouse
Publications and helpful links
General Publications
- Canivet C, Costa N, Ory-Magne F, Arcari C, Mohara C, Pourcel L, Derumeaux H, Berard E, Bourrel R, Molinier L, Brefel-Courbon C. Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients: A Randomized Controlled Trial. PLoS One. 2016 Sep 29;11(9):e0162646. doi: 10.1371/journal.pone.0162646. eCollection 2016.
- Ory Magne F, Arcari C, Canivet C, Sarrail M, Fabre MH, Mohara C, Brefel Courbon C. [A therapeutic educational program in Parkinson's disease: ETPARK]. Rev Neurol (Paris). 2014 Feb;170(2):128-33. doi: 10.1016/j.neurol.2013.08.007. Epub 2013 Nov 20. French.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/19/0183
- 2019-A02754-53 (Other Identifier: ID-RCB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Therapeutic education workshop
-
Washington University School of MedicineRecruiting
-
University of UtahVA Salt Lake City Health Care SystemWithdrawn
-
Hospital for Special Surgery, New YorkWithdrawnACL InjuryUnited States
-
Gerencia de Atención Primaria, MadridActive, not recruitingFear of Falling | Falls | NursingSpain
-
Roy La Touche ArbizuUniversidad Autonoma de Madrid; Centro Universitario La Salle; Servicio Madrileño...UnknownLow Back Pain | Chronic Nonspecific Low Back PainSpain
-
Duke UniversityNot yet recruitingNerve Blocks | Medical Education in Emergency Ultrasound | Medical Education, Simulation, Crisis Resource ManagementUnited States
-
Nantes University HospitalTerminated
-
Centre de Recherche de l'Institut Universitaire...Canadian Institutes of Health Research (CIHR); Medical Research Council; Fonds... and other collaboratorsCompletedQuality of Life | Urinary Incontinence | Falls, Accidental | StigmaCanada, France, United Kingdom
-
University of CalgaryCanadian Institutes of Health Research (CIHR)Completed
-
Assistance Publique - Hôpitaux de ParisCentre Leon Berard; Ministry of Health, France; Université Montpellier; Telecom... and other collaboratorsUnknownKidney Transplantation | End-stage Renal Disease | Dialysis